Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.45 |
| ▸ | CCR1 | P32246 | 6/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL567998 | 0.87 | CCR1 (0.55) | CCR1MAPK14 | |
| SCHEMBL568160 | 0.87 | NR3C1 (0.43) | SMN1; SMN2CCR1 | |
| SCHEMBL3466361 | 0.83 | CCR1 (0.43) | L3MBTL1NR4A3CCR1 | |
| SCHEMBL15158549 | 0.76 | ALDH1A1 (0.47) | POLBMAPTSMN1; SMN2MAPK1CYP17A1 | |
| SCHEMBL20413782 | 0.76 | ALDH1A1 (0.47) | POLBMAPTSMN1; SMN2MAPK1TP53 | |
| SCHEMBL3439328 | 0.73 | KDM4E (0.37) | MAPK1 | |
| SCHEMBL6390136 | 0.72 | ALDH1A1 (0.48) | POLBMAPTSMN1; SMN2MAPK14TP53 | |
| SCHEMBL17982137 | 0.72 | MAPT (0.44) | POLBMAPTL3MBTL1NR4A3SMN1; SMN2 | |
| SCHEMBL12800131 | 0.72 | CCR1 (0.50) | CCR1CYP17A1CYP1A2 | |
| SCHEMBL1135201 | 0.72 | CCR1 (0.61) | CCR1MAPK14CYP17A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8871786-B2 | Azaindazole amide compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-28 | — | — | US | disclosed |
| US-20130203803-A1 | Azaindazole Amide Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-08 | — | — | US | disclosed |
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | POLB 2974/4885MAPT 4650/4885L3MBTL1 4281/4885 |
| US-20130203803-A1 | Azaindazole Amide Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | POLB 3178/4885MAPT 4441/4885L3MBTL1 4123/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | POLB 1195/4885MAPT 4278/4885L3MBTL1 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.